Introduction
The angiotensin-I converting inhibitor, captopril, has been used to control severe hypertension in doses of up to 450 mg daily (Brunner et al., 1978; Brunner et al., 1979) . A number of adverse effects have been reported with the drug (Atkinson et al., 1980) and in view of its renal excretion (Kripalani et al., 1980) a reduced dosage regime has been recommended for patients with renal impairment.
We report six patients with severe refractory hypertension and chronic renal failure whose blood pressure has been effectively controlled by the use of a low dose of captopril ( Captopril in a daily dose of 450 mg in combination with frusemide has proved to be effective therapy for severe refractory hypertension (Brunner et al., 1979; Atkinson et al., 1980) . Although the renin-angiotensin system is effectively inhibited by a single dose of less than 25 mg of captopril, the hypotensive effect is short-lived (Swartz et al., 1980) , as captopril is thought to be cleared from the circulation within 6 hr (Kripalani et al., 1980) . The high renal clearance (70%) of the drug suggests that accumulation is liable to occur in patients with renal failure and in view of the adverse effects associated with captopril (Atkinson et al., 1980) a reduced dosage regime has been recommended for use in such patients. This study demonstrates that in patients with renal failure significantly improved blood pressure control can be achieved when a low dose of captopril is combined with other therapy which may either increase the dependency of the blood pressure on the renin-angiotensin system, e.g. sodium restriction and diuretics (Oelkers et al., 1974) Captopril can cause a number of severe adverse effects. White et al. (1980) noted that in patients with renal impairment receiving 450 mg of captopril a day severe hyperkalaemia exceeding 6 mmol/litre occurred in 3 patients. Our data indicate that hyperkalaemia remains a particular problem in patients with chronic renal failure despite using low dose captopril. However, the blood dyscrasias (Gavras et al., 1981; El Matri et al., 1981) and nephropathy (Hoorntje et al., 1980) previously reported after standard dose captopril therapy have not, to date, developed in any of our patients. 
